Vaxcyte

Vaxcyte is a clinical-stage vaccine innovation company dedicated to eliminating bacterial infections. They are headquartered in San Carlos, California and are driven by a mission to protect humankind from the devastating consequences of bacterial diseases. Their unique approach involves re-engineering how complex vaccines are made, utilizing advanced chemistry and a proprietary cell-free protein synthesis platform called XpressCF™. This platform allows them to create high-fidelity vaccines that are uniquely capable of breaking down bacteria's complex defense mechanisms while preserving immunogenicity.

Vaxcyte's current pipeline includes several vaccine candidates targeting various bacterial infections, including invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV), has been granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults. Vaxcyte is also developing VAX-31, a broader-spectrum PCV candidate, as well as preclinical programs for Group A Strep, periodontitis, and Shigella.

Vaxcyte offers a hybrid work schedule, allowing employees to split their time between working remotely and in the office. The specific arrangement varies by role, with some positions offering full-time remote work. While not all jobs offer full flexibility, Vaxcyte prioritizes a work-life balance and encourages employees to discuss their individual needs with their managers.

Vaxcyte offers a comprehensive benefits package to its employees, including health insurance, a 401k plan with a matching program, flexible paid time off and holidays, equity awards, dental insurance, vision insurance, a health savings account (HSA) contribution, flexible spending accounts (FSA), paid sick leave, basic life/AD&D insurance, short and long-term disability insurance, health activity and commuter programs, and an employee assistance program.

Vaxcyte is a clinical-stage vaccine innovation company dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. They believe that by re-engineering the way complex vaccines are made using advanced chemistry and their XpressCF™ cell-free protein synthesis platform, they can create high-fidelity vaccines that protect humankind from the devastating consequences of bacterial diseases.

Vaxcyte fosters a collaborative and supportive work environment, prioritizing kindness and inclusion in their pursuit of groundbreaking vaccine development. They value ambition and innovation, encouraging employees to think outside the box and push the boundaries of what's possible in the fight against bacterial diseases. The company emphasizes a commitment to excellence, integrity, and open communication, creating a culture that encourages both individual growth and team success.

Vaxcyte strives to foster a diverse, equitable, and inclusive workplace by promoting a culture of kindness and respect. They believe in creating a welcoming environment where everyone feels valued, heard, and empowered to contribute their unique talents and perspectives. Vaxcyte prioritizes equitable opportunities for all employees, regardless of background or identity, and actively seeks to build a team that reflects the diversity of the communities they serve.